Logo image of BLPH

BELLEROPHON THERAPEUTICS INC (BLPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLPH - US0787713009 - Common Stock

0.1025 USD
-0.28 (-73.39%)
Last: 10/13/2023, 8:00:02 PM
0.114 USD
+0.01 (+11.22%)
After Hours: 10/13/2023, 8:00:02 PM
Fundamental Rating

2

BLPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. The financial health of BLPH is average, but there are quite some concerns on its profitability. BLPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BLPH had negative earnings in the past year.
  • BLPH had a negative operating cash flow in the past year.
BLPH Yearly Net Income VS EBIT VS OCF VS FCFBLPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

  • BLPH has a Return On Assets of -110.28%. This is amonst the worse of the industry: BLPH underperforms 81.59% of its industry peers.
  • BLPH has a Return On Equity of -220.54%. This is in the lower half of the industry: BLPH underperforms 74.63% of its industry peers.
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROIC N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
BLPH Yearly ROA, ROE, ROICBLPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K 1.5K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BLPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLPH Yearly Profit, Operating, Gross MarginsBLPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, BLPH has more shares outstanding
  • BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BLPH Yearly Shares OutstandingBLPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
BLPH Yearly Total Debt VS Total AssetsBLPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -34.54, we must say that BLPH is in the distress zone and has some risk of bankruptcy.
  • BLPH has a worse Altman-Z score (-34.54) than 94.86% of its industry peers.
  • BLPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.54
ROIC/WACCN/A
WACCN/A
BLPH Yearly LT Debt VS Equity VS FCFBLPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

  • BLPH has a Current Ratio of 2.00. This indicates that BLPH is financially healthy and has no problem in meeting its short term obligations.
  • BLPH has a worse Current ratio (2.00) than 81.92% of its industry peers.
  • A Quick Ratio of 2.00 indicates that BLPH has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.00, BLPH is not doing good in the industry: 80.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 2
BLPH Yearly Current Assets VS Current LiabilitesBLPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

  • BLPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.27%, which is quite impressive.
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BLPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.86% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLPH Yearly Revenue VS EstimatesBLPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
BLPH Yearly EPS VS EstimatesBLPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • BLPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLPH Price Earnings VS Forward Price EarningsBLPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLPH Per share dataBLPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BLPH's earnings are expected to grow with 39.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y39.61%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BLPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLEROPHON THERAPEUTICS INC

NASDAQ:BLPH (10/13/2023, 8:00:02 PM)

After market: 0.114 +0.01 (+11.22%)

0.1025

-0.28 (-73.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14
Earnings (Next)11-13
Inst Owners0.13%
Inst Owner Change0%
Ins Owners192.64%
Ins Owner Change0%
Market Cap1.25M
Revenue(TTM)5.64M
Net Income(TTM)-12.40M
Analysts43.33
Price Target2.04 (1890.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.72%
Min EPS beat(2)1.96%
Max EPS beat(2)153.48%
EPS beat(4)3
Avg EPS beat(4)39.59%
Min EPS beat(4)-8.25%
Max EPS beat(4)153.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.53%
EPS NY rev (1m)0%
EPS NY rev (3m)28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.46
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.28%
ROE -220.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.74%
ROA(5y)-90.23%
ROE(3y)-309.79%
ROE(5y)-245.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 2
Altman-Z -34.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.33%
EPS Next Y50.96%
EPS Next 2Y5.24%
EPS Next 3Y39.61%
EPS Next 5Y22.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.17%
OCF growth 3YN/A
OCF growth 5YN/A

BELLEROPHON THERAPEUTICS INC / BLPH FAQ

What is the ChartMill fundamental rating of BELLEROPHON THERAPEUTICS INC (BLPH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BLPH.


Can you provide the valuation status for BELLEROPHON THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BELLEROPHON THERAPEUTICS INC (BLPH). This can be considered as Overvalued.


How profitable is BELLEROPHON THERAPEUTICS INC (BLPH) stock?

BELLEROPHON THERAPEUTICS INC (BLPH) has a profitability rating of 0 / 10.


What is the expected EPS growth for BELLEROPHON THERAPEUTICS INC (BLPH) stock?

The Earnings per Share (EPS) of BELLEROPHON THERAPEUTICS INC (BLPH) is expected to grow by 50.96% in the next year.